The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation.

Suresh S.  Ramalingam

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Novartis

Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer

Yuri  Rukazenkov

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Karen  Thomas

Employment - AstraZeneca; Shire

Jean-Charles  Soria

Honoraria - AstraZeneca

Consulting or Advisory Role - AstraZeneca